Analysts defend Abbott Labs' stock after Thursday's 'too punitive' sell-off

The market saw muted activity despite the S&P 500 briefly hitting an all-time high, buoyed by University of Michigan data showing lower inflation expectations and improved consumer confidence, which also nudged the 10-year Treasury yield lower. This comes as Fed Governor Waller signaled support for a rate cut, hinting at potential FOMC dissent. Separately, Abbott Laboratories rallied following a Jefferies upgrade to Buy, with analysts deeming Thursday's 8.5% sell-off on a growth outlook cut "too punitive" and transitory, while DuPont was named a "catalyst call buy idea" by Deutsche Bank, anticipating significant value unlocking from its electronics business spinoff in November due to its current valuation discount. Investors also anticipate upcoming earnings from Danaher, Capital One, GE Vernova, Honeywell, and Dover.

Analysis

The broader market is exhibiting tentative strength, with the S&P 500 briefly reaching a new all-time high on favorable University of Michigan data showing lower inflation expectations and improved consumer sentiment, which also pressured the 10-year Treasury yield lower. This macro backdrop is complicated by signals of potential dissent within the Federal Reserve, as Governor Christopher Waller expressed support for a rate cut, contrasting with market expectations for a hold until September. On a micro level, Abbott Laboratories (ABT) is rebounding following an 8.5% sell-off, which both company management and Jefferies analysts have characterized as a 'too punitive' overreaction to a slight guidance cut. The downgrade was attributed to a transitory headwind in its China diagnostics business, with analysts highlighting strong fundamentals and potential for accelerated growth in 2026. In another key development, DuPont (DD) has been identified by Deutsche Bank as a 'catalyst call buy idea' due to a significant valuation gap ahead of its electronics business spinoff on November 1. DuPont currently trades at 11.1 times its 2025 EBITDA, a steep discount to its closest peer, Entegris, which trades at 18.8 times, suggesting the separation could unlock substantial shareholder value.

Key Decisions for Investors

• Given that both management and analysts view Abbott's recent 8.5% stock decline as an overreaction, investors with a longer-term horizon could view the current price as an attractive entry point ahead of projected growth acceleration in 2026.
• Investors should closely examine DuPont ahead of its upcoming earnings and November 1 spinoff, as the significant valuation discount relative to peers presents a clear, catalyst-driven opportunity for potential value realization.
• While supportive economic data provides a positive tailwind, the signal of dissent within the Fed suggests investors should remain vigilant and monitor upcoming earnings from bellwethers like Danaher, Honeywell, and Capital One for further confirmation of economic and corporate health.